# Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

> **NCT07077798** · NA · NOT_YET_RECRUITING · sponsor: **Wan-Guang Zhang** · enrollment: 234 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07077798
- **Lead sponsor:** Wan-Guang Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077798, "Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07077798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*